| NCT00563433 | Diabetic Foot Ulcers | Drug: ofloxacin|Drug: MSI-78 | MacroChem Corporation|Genaera Corporation | Phase 3 | 1994-08-01 | 2007-11-21 |
| NCT00563394 | Diabetic Foot Ulcers | Drug: ofloxacin|Drug: MSI-78 | MacroChem Corporation|Genaera Corporation | Phase 3 | 1994-08-01 | 2007-11-21 |
| NCT01573910 | Bacterial Conjunctivitis | Drug: Moxifloxacin ophthalmic solution, 0.5%|Drug: Ofloxacin ophthalmic solution, 0.3% | Alcon Research | Phase 3 | 2012-05-01 | 2015-04-27 |
| NCT00176306 | Obesity|Critical Illness | Drug: Levofloxacin 750 mg IV | University of Kentucky|Ortho-McNeil Pharmaceutical | Phase 4 | 2005-01-01 | 2012-09-12 |
| NCT01371656 | Acute Leukemias of Ambiguous Lineage|Bacterial Infection|Diarrhea|Fungal Infection|Musculoskeletal Complications|Neutropenia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies | Drug: levofloxacin | Children's Oncology Group|National Cancer Institute (NCI) | Phase 3 | 2011-06-01 | 2017-02-13 |
| NCT02018081 | Intensive Care Unit Syndrome|Community-acquired Pneumonia | Drug: Levofloxacin | University Hospital, Toulouse | Phase 4 | 2012-03-01 | 2015-03-04 |
| NCT01055145 | TB | Drug: levofloxacin, moxifloxacin | Seoul National University Hospital | Phase 3 | 2010-03-01 | 2012-11-22 |
| NCT00645437 | Renal Diseases | Drug: Levofloxacin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2004-10-01 | 2011-06-06 |
| NCT00002249 | HIV Infections | Drug: Levofloxacin | R W Johnson Pharmaceutical Research Institute|NIH AIDS Clinical Trials Information Service | Phase 1 | null | 2005-06-23 |
| NCT00621387 | Reactive Arthritis | Drug: ofloxacin and roxithromycin|Drug: placebo | Helsinki University | | 1993-11-01 | 2008-02-11 |
| NCT01761201 | Latent Tuberculosis Infection|Infection in Solid Organ Transplant Recipients | Drug: Levofloxacin|Drug: Isoniazid | Fundaci贸n P煤blica Andaluza para la gesti贸n de la Investigaci贸n en Sevilla|Spanish Network for Research in Infectious Diseases | Phase 3 | 2012-01-01 | 2014-08-05 |
| NCT00764582 | Corneal Transplantation | Drug: 1.5% levofloxacin ophthalmic solution|Drug: 0.5% moxifloxacin ophthalmic solution | Santen Inc.|Vistakon Pharmaceuticals | Phase 4 | 2008-09-01 | 2009-08-24 |
| NCT01168713 | Community-Acquired Bacterial Pneumonia | Drug: Levofloxacin|Drug: CEM-101 | Cempra Inc | Phase 2 | 2010-08-01 | 2017-03-01 |
| NCT01978938 | Complicated Urinary Tract Infections (cUTI) | Drug: Eravacycline|Drug: Levofloxacin | Tetraphase Pharmaceuticals, Inc. | Phase 3 | 2013-12-01 | 2016-05-24 |
| NCT01529476 | Pneumonia | Drug: Levofloxacin|Drug: Nemonoxacin | TaiGen Biotechnology Co., Ltd.|Qualitix Clinical Research Co., Ltd.|Parexel|PPD | Phase 3 | 2011-04-01 | 2013-06-17 |
| NCT01524302 | Pneumonia, Bacterial|Community-acquired | Drug: Ceftaroline|Drug: Levofloxacin | Gary E. Stein, Pharm.D.|Forest Laboratories|Michigan State University | Phase 4 | 2012-02-01 | 2016-03-14 |
| NCT02884713 | GASTRITIS | Drug: Levofloxacin|Drug: Doxycycline|Drug: Esomeprazole | King Faisal Specialist Hospital & Research Center | | 2013-06-01 | 2016-08-25 |
| NCT01575899 | Helicobacter Pylori Infection | Drug: Levofloxacin-Amox/clav.|Drug: Clarithromycin-Amoxicillin | Buddhist Tzu Chi General Hospital | Phase 4 | 2007-12-01 | 2012-07-28 |
| NCT00035347 | Community-Acquired Pneumonia (CAP) | Drug: IV azithromycin|Drug: ceftriaxone|Drug: oral azithromycin|Drug: IV levofloxacin|Drug: oral levofloxacin | Pfizer | Phase 4 | 2001-01-01 | 2017-03-07 |
| NCT01537055 | Eradication Rate for Helicobacter | Drug: levofloxacin-based sequential therapy|Drug: levofloxacin-based triple therapy for 10 days | National Taiwan University Hospital|E-DA Hospital | Phase 4 | 2012-02-01 | 2015-01-30 |
